Ralph Tiedt
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ralph Tiedt.
Blood | 2009
Ralph Tiedt; Jörn Coers; Sandra Ziegler; Adrian Wiestner; Hui Hao-Shen; Caroline Bornmann; Johannes Schenkel; Svetlana Karakhanova; Frederic J. de Sauvage; Carl W. Jackson; Radek C. Skoda
We generated mice expressing a full-length Mpl transgene under the control of a 2-kb Mpl promoter in an Mpl(-/-) background, effectively obtaining mice that express full-length Mpl in the absence of other Mpl isoforms. These mice developed thrombocytosis with platelet levels approximately 5-fold higher than wild-type controls and markedly increased megakaryocyte numbers. The reintroduction of one wild-type Mpl allele restored normal platelet counts. We excluded the deletion of Mpl-tr, a dominant-negative isoform, as the underlying molecular cause for thrombocytosis. Instead, we found that transgene expression driven by the 2-kb Mpl promoter fragment was decreased during late megakaryocyte maturation, resulting in strongly diminished Mpl protein expression in platelets. Because platelets exert a negative feedback on thrombopoiesis by binding and consuming Tpo in the circulation through Mpl, we propose that the severe reduction of Mpl protein in platelets in Mpl-transgenic Mpl(-/-) mice shifts the equilibrium of this feedback loop, resulting in markedly elevated levels of megakaryocytes and platelets at steady state. Although the mechanism causing decreased expression of Mpl protein in platelets from patients with myeloproliferative disorders differs from this transgenic model, our results suggest that lowering Mpl protein in platelets could contribute to raising the platelet count.
Haematologica | 2008
Kun Liu; Robert Kralovics; Zbigniew Rudzki; Barbara Grabowska; Andreas Buser; Damla Olcaydu; Heinz Gisslinger; Ralph Tiedt; Patricia Frank; Krzysztof Okoń; Anthonie P.C. van der Maas; Radek C. Skoda
Familial thrombocytosis may be associated with gain-of-function mutations in the thrombopoietin (THPO) gene, or an activating germline mutation of MPL, the gene encoding thrombopoietin receptor. This study of a large family with thrombocytosis associated with a germline THPO mutations illustrates the hematologic and clinical features of this rare condition. See related article on page 646. Background Hereditary thrombocythemia is an autosomal dominant disorder with clinical features resembling sporadic essential thrombocythemia. Germline mutations in families with hereditary thrombocythemia have been identified in the gene for thrombopoietin (TPHO) and its receptor, MPL. Design and Methods Here we characterized a THPO mutation in a hereditary thrombocythemia pedigree with 11 affected family members. Results Affected family members carry a G → C transversion in the splice donor of intron 3 of THPO that co-segregated with thrombocytosis within the pedigree. We previously described the identical mutation in a Dutch family with hereditary thrombocythemia. Haplotype analysis using single nucleotide polymorphisms surrounding the mutation indicated that the mutations arose independently in the two families. MPL protein levels, but not mRNA levels, were low in platelets from affected family members. Bone marrow histology showed features compatible with those of essential thrombocythemia, but the megakaryocytes were unusually compact, as assessed by planimetric analysis. Impaired microcirculation resulting in brief episodes of fainting and dizziness that responded well to aspirin were the predominant clinical features in a total of 23 affected family members studied. Disease onset is earlier in patients with hereditary thrombocythemia than in those with essential thrombocythemia, but the frequencies of thrombotic, vascular and hemorrhagic events are similar in the two groups. Conclusions A mutation in THPO occurred de novo in the same position as in a previously described family with hereditary thrombocythemia. Patients with this mutation have elevated serum levels of thrombopoietin and a phenotype that responds to aspirin and does not require cytoreductive treatment.
Journal of Cell Biology | 2007
Brian G. Petrich; Patrizia Marchese; Zaverio M. Ruggeri; Saskia Spiess; Rachel A.M. Weichert; Feng Ye; Ralph Tiedt; Radek C. Skoda; Susan J. Monkley; David R. Critchley; Mark H. Ginsberg
Petrich et al. 2007. J. Exp. Med. doi:10.1084/jem.20071800[OpenUrl][1][Abstract/FREE Full Text][2] [1]: {openurl}?query=rft.jtitle%253DJ.%2BExp.%2BMed.%26rft_id%253Dinfo%253Adoi%252F10.1084%252Fjem.20071800%26rft_id%253Dinfo%253Apmid%252F18086863%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%
The New England Journal of Medicine | 2005
Robert Kralovics; Francesco Passamonti; Andreas Buser; Soon-Siong Teo; Ralph Tiedt; Jakob Passweg; André Tichelli; Mario Cazzola; Radek C. Skoda
Blood | 2008
Ralph Tiedt; Hui Hao-Shen; Marta Sobas; Renate Looser; Stephan Dirnhofer; Jürg Schwaller; Radek C. Skoda
Blood | 2007
Ralph Tiedt; Tibor Schomber; Hui Hao-Shen; Radek C. Skoda
Blood | 2005
Robert Kralovics; Soon Siong Teo; Andreas Buser; Martin Brutsche; Ralph Tiedt; André Tichelli; Francesco Passamonti; Daniela Pietra; Mario Cazzola; Radek C. Skoda
Blood | 2007
Catherine Léon; Anita Eckly; Béatrice Hechler; Boris Aleil; Monique Freund; Catherine Ravanat; Marie Jourdain; Christelle Nonne; Josiane Weber; Ralph Tiedt; Marie-Pierre Gratacap; Sonia Severin; Jean-Pierre Cazenave; François Lanza; Radek C. Skoda; Christian Gachet
Blood | 2006
Ralph Tiedt; Hui Hao-Shen; Radek C. Skoda
Blood | 2006
Ian S. Hitchcock; Norma E. Fox; Katherine Sear; Ralph Tiedt; Radek Skoda; Kenneth Kaushansky